Natalie Reizine, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    EMD Serono
    Date added:
    09/25/2023
    Date updated:
    09/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Merck
    Date added:
    09/25/2023
    Date updated:
    09/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    AstraZeneca
    Date added:
    09/25/2023
    Date updated:
    09/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Tempus
    Date added:
    09/25/2023
    Date updated:
    09/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Sanofi
    Date added:
    09/25/2023
    Date updated:
    09/25/2023
    Relationship end date:
    09/14/2022
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Exelexis
    Date added:
    09/25/2023
    Date updated:
    09/25/2023
    Relationship end date:
    12/22/2022
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Janssen
    Date added:
    09/25/2023
    Date updated:
    09/25/2023
    Relationship end date:
    07/03/2023
Return to PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice